相关实验视频

Updated: Jul 17, 2026

Stereotactic Radiosurgery for Gynecologic Cancer

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

肝硬化进展的贡献在肝功能障碍后的刻板体体辐射疗法

Alex K Bryant¹, John D Rice², Emily Morris²

¹Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan; Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.

International journal of radiation oncology, biology, physics

|July 25, 2025

概括

肝硬化进展显著影响肝细胞癌 (HCC) 的立体体辐射疗法 (SBRT) 后肝功能下降. 这项研究量化了肝硬化进展,而不仅仅是辐射毒性,对SBRT后肝功能恶化有着重大影响.

科学领域:

肝病学肝病学是一种肝病学.
辐射瘤学辐射瘤学
医学统计医学统计

背景情况:

肝硬化和肝细胞癌 (HCC) 患者在立体体辐射疗法 (SBRT) 后经常经历肝功能恶化.
直接辐射毒性与肝硬化自然进展对这种下降的确切贡献尚不清楚.

研究的目的:

估计SBRT后白蛋白-白素 (ALBI) 评分恶化的比例,这是由于肝硬化进展而不是直接辐射毒性.
为了区分治疗诱导的毒性和肝功能下降的疾病进展.

主要方法:

开发了混合效应模型,使用6789名没有HCC的肝硬化患者的数据来预测由于肝硬化进展而导致的ALBI得分变化.
将该模型应用于一组260名肝硬化和HCC患者的SBRT治疗队列,以预测仅仅由肝硬化引起的ALBI恶化.
将预测的ALBI轨迹与观察到的轨迹进行比较,以确定由于肝硬化而导致的变化的比例与SBRT.

主要成果:

纵向建模显示了肝硬化中的非线性ALBI轨迹,最初的改善随后是平均年度恶化.
在接受SBRT治疗的HCC队列中,ALBI得分从12个月的中位数 -2.19 恶化到 -1.86.
在SBRT后12个月,估计24.9% (95% CI,15.0%-34.7%) 的ALBI得分恶化归因于肝硬化进展,其余部分是由于SBRT.

结论:

在患有肝硬化和HCC的患者中,SBRT后肝功能下降的显著且越来越多的比例是由于肝病的自然进展.
这些发现对于准确估计SBRT治疗毒性和管理患者期望至关重要.

更多相关视频

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Cirrhosis I: Introduction

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

Cirrhosis II: Pathophysiology

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...